Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours

Immune checkpoint inhibitors (ICIs) have been developed for canine tumour treatment, and pilot clinical studies have demonstrated their antitumour efficacy in dogs with oral malignant melanoma (OMM). Although ICIs have been approved for various human malignancies, their clinical benefits in other tumour types remain to be elucidated in dogs. Here, we conducted a clinical study of c4G12, a canine chimeric anti-PD-L1 antibody, to assess its safety and efficacy in dogs with various advanced malignant tumours (n = 12) at the Veterinary Teaching Hospital of Hokkaido University from 2018 to 2023. Dogs with digit or foot pad malignant melanoma (n = 4), osteosarcoma (n = 2), hemangiosarcoma (n = 1), transitional cell carcinoma (n = 1), nasal adenocarcinoma (n = 1), B-cell lymphoma (n = 1), or undifferentiated sarcoma (n = 2) were treated with 2 or 5 mg/kg c4G12 every 2 weeks. Treatment-related adverse events of any grade were observed in eight dogs (66.7%), including elevated aspartate aminotransferase (grade 3) in one dog (8.3%) and thrombocytopenia (grade 4) in another dog (8.3%). Among dogs with target disease at baseline (n = 8), as defined by the response evaluation criteria for solid tumours in dogs (cRECIST), one dog with nasal adenocarcinoma and another with osteosarcoma experienced a partial response (PR), with an objective response rate of 25.0% (2 PR out of 8 dogs; 95% confidence interval: 3.2–65.1%). These results suggest that c4G12 is safe and tolerable and shows antitumor effects in dogs with malignant tumours other than OMM. Further clinical studies are warranted to identify the tumour types that are most likely to benefit from c4G12 treatment.

[1]  M. Okumura,et al.  Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines. , 2023, Veterinary and comparative oncology.

[2]  M. Santoni,et al.  Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis , 2023, Cancer Immunology, Immunotherapy.

[3]  T. Hupp,et al.  Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma , 2022, Cancers.

[4]  Marcel P. Trefny,et al.  Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment , 2022, Science Translational Medicine.

[5]  M. Nakaichi,et al.  Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report. , 2022, Veterinary and comparative oncology.

[6]  C. Lacchetti,et al.  Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. , 2022, JCO oncology practice.

[7]  G. Brandi,et al.  Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects , 2021, Expert opinion on investigational drugs.

[8]  C. Yee,et al.  Hematologic complications of immune checkpoint inhibitors , 2021, Blood.

[9]  D. Thamm,et al.  Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Takashi Kimura,et al.  Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages , 2021, Scientific Reports.

[11]  K. Ohashi,et al.  PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma , 2021, npj Precision Oncology.

[12]  W. Hennink,et al.  Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other? , 2021, Theranostics.

[13]  Kongming Wu,et al.  Regulation of PD-L1 expression in the tumor microenvironment , 2021, Journal of Hematology & Oncology.

[14]  Jun Wang,et al.  Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review , 2020, Frontiers in Oncology.

[15]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[16]  M. Nakaichi,et al.  A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs , 2020, Scientific Reports.

[17]  G. Johnson,et al.  Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma , 2020, Journal of veterinary internal medicine.

[18]  K. Ohashi,et al.  Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers , 2020, Frontiers in Veterinary Science.

[19]  T. Nakano,et al.  Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment , 2020, International Journal of Clinical Oncology.

[20]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[21]  T. Yonezawa,et al.  CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer , 2019, Cancer Immunology Research.

[22]  S. Sudarsanam,et al.  Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases , 2019, Modern Pathology.

[23]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[24]  D. Knapp,et al.  Canine (Pet Dog) Tumor Microsurgery and Intratumoral Concentration and Safety of Metronomic Chlorambucil for Spontaneous Glioma: A Phase I Clinical Trial. , 2018, World neurosurgery.

[25]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[26]  H. Weng,et al.  Retrospective comparison of three doses of metronomic chlorambucil for tolerability and efficacy in dogs with spontaneous cancer† , 2017, Veterinary and comparative oncology.

[27]  K. Ohashi,et al.  A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma , 2017, Scientific Reports.

[28]  A. Caldwell,et al.  Immune regulation of canine tumour and macrophage PD‐L1 expression , 2017, Veterinary and comparative oncology.

[29]  Tasuku Honjo,et al.  Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.

[30]  K. Ohashi,et al.  Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.

[31]  Kumi Y. Inoue,et al.  Programmed Cell Death Ligand 1 Expression in Canine Cancer. , 2016, In vivo.

[32]  D. Thamm,et al.  Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.

[33]  K. Sugiura,et al.  A current life table and causes of death for insured dogs in Japan. , 2015, Preventive veterinary medicine.

[34]  T. Fan,et al.  The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review , 2015, Journal of veterinary internal medicine.

[35]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[36]  K. Ohashi,et al.  Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade , 2014, PloS one.

[37]  D. Knapp,et al.  Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. , 2013, Journal of the American Veterinary Medical Association.

[38]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[39]  M. Sznol,et al.  Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer , 2013, Clinical Cancer Research.

[40]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[41]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[42]  V. Adams,et al.  Methods and mortality results of a health survey of purebred dogs in the UK. , 2010, The Journal of small animal practice.

[43]  N. Toft,et al.  Data from the Danish Veterinary Cancer Registry on the occurrence and distribution of neoplasms in dogs in Denmark , 2010, Veterinary Record.

[44]  John Launer Supervision , 2008, Postgraduate Medical Journal.

[45]  P. Bergman Canine oral melanoma. , 2007, Clinical techniques in small animal practice.

[46]  M. Salah,et al.  Methodology , 2003 .

[47]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[48]  J. Wood,et al.  Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. , 2002, The Journal of small animal practice.

[49]  R. Bronson Variation in age at death of dogs of different sexes and breeds. , 1982, American journal of veterinary research.

[50]  D. Y. Kim,et al.  Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors , 2017, Veterinary and comparative oncology.

[51]  Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.

[52]  R. Neal PROJECT ADMINISTRATION , 2009 .

[53]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.